Stephen Ward – VJRegenMed

Shaping the future of CMC in cell & gene therapy

admin_vjr_user — Mon, 05 Jul 2021 13:47:06 +0000

Stephen Ward, PhD, Cell and Gene Therapy Catapult, London, UK, provides an overview of the current Chemistry, Manufacturing and Controls (CMC) landscape in the cell and gene therapy industry and outcomes from a panel discussion on CMC at Cell & Gene Meeting on the Mediterranean 2021. He describes some of the important considerations and recommendations for developers that were discussed, including early investment in CMC, a focus on product characterization at an early stage and the utilization of platforms and technologies to build a pathway toward scalability. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Advancing the sector: training, scalability & materials standardization

admin_vjr_user — Mon, 05 Jul 2021 13:47:05 +0000

Stephen Ward, PhD, Cell and Gene Therapy Catapult, London, UK, discusses some of the key remaining barriers to the commercialization of cell and gene therapies. He describes a current skills shortage within the field and introduces the recently launched Advanced Therapies Skills Training Network (ATSTN), which aims to provide apprenticeship and cross skilling opportunities to help build the UK’s cell and gene therapy workforce. Dr Ward also highlights the importance of focusing on clinical interfacing and scalability, as well as supply chain solutions and the standardization of materials used to develop therapies. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Horizon scanning for the UK cell & gene therapy sector

admin_vjr_user — Mon, 05 Jul 2021 13:47:04 +0000

Stephen Ward, PhD, Cell and Gene Therapy Catapult, London, UK, provides an overview of the current cell and gene therapy landscape in the UK and looks ahead to the future. The UK’s cell and gene therapy sector currently receives a high level of support from the UK government which has helped to drive product development, manufacturing capability and adoption into healthcare systems. Going forward, Dr Ward expects the sector to continue to build on the strong infrastructure already in place in the UK and take advantage of innovation platforms and manufacturing facilities. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

The lasting impact of COVID-19 on the CGT sector

admin_vjr_user — Mon, 05 Jul 2021 13:47:02 +0000

Stephen Ward, PhD, Cell and Gene Therapy Catapult, London, UK, discusses the potential long-term impact of the COVID-19 pandemic on the cell and gene therapy sector, which saw significant advances in vaccine development, manufacture and distribution. Dr Ward highlights the flexibility of manufacturing facilities, the use of rapid scale-up technologies, accelerated technology transfer programs and collaborative working as key learnings from the pandemic that should be taken forward in the cell and gene therapies sector. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.